$AKER News
Last published 1mo ago
- 1mo agoMSFTAPLDORCLNVDA+2Nscale’s IPO will test Wall Street’s appetite for concentrated AI bets once againTechCrunch
- 5y agoAKERAkers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of MergerBusiness WireBALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (“Akers”) (Nasdaq: AKER) and MyMD Pharmaceuticals, Inc. (“MYMD”) today announced that at Akers’ special meeting of stockholders held on April 15, 2021, Akers obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Akers and MYMD. MYMD previously obtained a sufficient number of written co ...
- 5y agoAKERAkers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression TrialBusiness WireBALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MY ...
- 5y agoAKERAkers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory BoardBusiness WireBALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Wharte ...
- 5y agoAKERAkers Biosciences Announces Shareholder Meeting to Vote on Business Combination with MyMD PharmaceuticalsBusiness WireBALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed business combination with MyMD Pharmaceuticals (“MyMD”). The meeting will be held on April 15, 2021 at 10:00 a.m., Eastern Time, and will be “virtual,” meaning that you can participate in the meeting o ...
- 5y agoAKERMyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins DiscoveryBusiness WireBALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence.
- 5y agoAKERStudy Identifies Effects of Temperature Changes on SARS-CoV-2 TransmissionBusiness WireBALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced a new study published in PLOS ONE authored by Adam Kaplin, M.D., Ph.D., Chief Scientific Officer of MyMD Pharmace ...
- 5y agoAKERAkers Biosciences Responds to Erroneous Earnings Call Press ReleaseBusiness WireNEW YORK--(BUSINESS WIRE)--Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name. The Company has not scheduled any earnings calls. The Company is investigat ...
- 5y agoAKERAkers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key PatentBusiness WireBALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”) was issued US Pat. No. 10,835,523 B2, titled “Method of Regulating Tumor Necrosis Factor-Alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation” by the United States Patent & Trademark Of ...
- 5y agoAKERREMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD PharmaceuticalsBusiness WireBALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to hold a video conference for investors on Wednesday, November 18, 2020 at 4:15 p.m. ET to provide additional context on the integrated company, the clinical pipeline and drug development plan, and the co ...
- 5y agoCGIXAKERTGCDNKNMoore Kuehn Encourages CGIX, AKER, TGC and DNKN Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoAKERAkers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger AgreementBusiness WireBALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (“Akers”) (NASDAQ: AKER) today jointly announced that they have entered into a definitive merger agreement. Upon closing the transaction, the combined company is expected to be renamed MyMD Pharmaceuticals, Inc. and remain listed on the Nasdaq under the new ticker symbol “MYMD.”
- 6y agoAKERAkers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept ResultsGlobeNewswireThorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its...
- 6y agoAKERAkers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireThorofare, New Jersey, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several...
- 6y agoAKERAkers Biosciences and Premas Biotech Announce Initiation of Animal StudiesGlobeNewswireCompany intends to cease focus on screening and testing products business Thorofare, New Jersey, July 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a...
- 6y agoAKERAkers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireThorofare, New Jersey, May 18, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of...
- 6y agoAKERAkers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireThorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
- 6y agoAKERAkers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLPGlobeNewswireThorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Premas...
- 6y agoAKERAkers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus AntigensGlobeNewswireThorofare, New Jersey, April 08, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its...
- 6y agoMBRXAKERABTPSTI+1Biotechs Fast Track Repurposing Existing Drugs for COVID-19 TreatmentsPR NewswireThe search for vaccines and treatments for the global health crises is now focusing on medicines that are presently approved for other ailments. A...
- 6y agoAKERAkers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireThorofare, New Jersey, April 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
- 6y agoAKERAkers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19GlobeNewswireSuccessfully obtained clones for all three selected Coronavirus Antigens Thorofare, New Jersey, April 06, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a...
- 6y agoAKERAkers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine CandidateGlobeNewswireThorofare, New Jersey, March 24, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced it will hold a...
- 6y agoAKERAkers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas BiotechGlobeNewswireEstablished D-Crypt™ platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candidates for CoronavirusCurrent Regulatory environment could lead to...
- 6y agoAKERAkers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative LitigationGlobeNewswireThorofare, New Jersey, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it reached...
- 6y agoAKERAkers BioSciences Regains Compliance with Nasdaq Listing StandardsGlobeNewswireThorofare, New Jersey, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, announced today that on...
- 6y agoAKERAkers BioSciences, Inc. Announces Closing of Approximately $8 Million Public OfferingGlobeNewswireThorofare, New Jersey, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the...
- 6y agoAKERAkers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, NevadaGlobeNewswireThorofare, New Jersey, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Executive...
- 6y agoAKERAkers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public OfferingGlobeNewswireThorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the...
- 6y agoAKERAkers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing IndustryGlobeNewswire· Establishes Advisory Board appointing Bob Hoban and Michael Patterson Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ:...
- 6y agoAKERAkers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock SplitGlobeNewswireTHOROFARE, N.J., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced that...
- 10y agoAKERAkers Biosciences' (AKER) CEO John Gormally on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoAKERAkers Biosciences' (AKER) on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts